Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Fasiglifam (TAK875) is a potent, selective and orally bioavailable GPR40 agonist.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 45.00 | |
5 mg | In stock | $ 97.00 | |
10 mg | In stock | $ 164.00 | |
25 mg | In stock | $ 298.00 | |
50 mg | In stock | $ 494.00 | |
100 mg | In stock | $ 597.00 | |
200 mg | In stock | $ 864.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 126.00 |
Description | Fasiglifam (TAK875) is a potent, selective and orally bioavailable GPR40 agonist. |
Targets&IC50 | FFA1/GPR40:72 nM.(EC50) |
In vitro | TAK-875 (0.01-10 μM) produces a concentration-dependent increase in intracellular IP production in CHO-hGPR40, with EC50 of 0.072 μM.?TAK-875 (0.1-10 μM) dose-dependently augments intracellular IP production in CHO cells[1]. TAK-875 (3-30 μM) concentration-dependently augments [Ca2+]i. In the presence of 10 mM glucose, TAK-875 (0.001-10 μM) dose-dependently stimulats insulin secretion from INS-1 833/15 cells[2]. |
In vivo | Administered orally, TAK-875 at a dose of 10 mg/kg enhances plasma insulin levels in ZDF rats. At a higher dosage of 30 mg/kg, it ameliorates fasting hyperglycemia without impacting fasting normoglycemia. Interestingly, a 3- to 10-fold increase in the dose that ameliorated glucose tolerance in diabetic models, specifically 30 mg/kg, does not modify fasting glucose levels in SD rats maintaining normal glucose homeostasis. Similarly, TAK-875 does not significantly affect insulin secretion in SD rats demonstrating normal fasting glucose levels [1]. |
Kinase Assay | INS-1 832/13 cells are suspended in RPMI medium containing 11 mM glucose and the supplements described above. These cells are seeded at a density of 2×104?cells/well in a 96-well black plate coated with poly-D-lysine, and 1% BSA and 0.1% DMSO alone (control), palmitic acid (62.5, 125, 250, 500, and 1000 μM), oleic acid (62.5, 125, 250, 500, and 1000 μM), or TAK-875 (6.25, 12.5, 25, 50, and 100 μM) is added to the plate with 1% BSA and 0.1% DMSO, followed by culture for 72 h. After the culture, caspase 3/7 activity is measured with the Apo-one homogeneous caspase 3/7 assay according to the manufacturer's instructions. Fluorescence intensity is measured at an excitation of 485 nm and an emission at 535 nm. |
Cell Research | TAK-875 is dissolved in 1% BSA and 0.1% DMSO.? INS-1 832/13 cells are suspended in RPMI medium and seeded in a 96-well plate at a density of 2×104 cells/well; 1% BSA and 0.1% DMSO alone (control), palmitic acid (10, 100, and 1000 μM), oleic acid (10, 100, and 1000 μM), or TAK-875 (1, 10, and 100 μM) is added to the plate. After 72-h culture, medium is discarded, and cells are preincubated for 2 h with KRBH containing 1 mM glucose and 0.2% BSA at 37°C. After discarding of the preincubation buffer, KRBH containing 1 or 20 mM glucose and 0.2% BSA is added, and the plate is further incubated for 2 h. The insulin concentration in the supernatant is measured as described above. To measure intracellular insulin content, INS-1 832/13 cells are exposed to 1% BSA and 0.1% DMSO alone (control), palmitic acid (1000 μM), oleic acid (1000 μM), or TAK-875 (100 μM) with 1% BSA and 0.1% DMSO. After incubation, cells are washed once with phosphate-buffered saline, and acid-ethanol solution is added to each well, followed by sonication on ice. Intracellular insulin is extracted by overnight incubation at ?30°C, followed by separation of supernatant by centrifugation at 12,000 rpm×5 min at 4°C. |
Synonyms | TAK875 |
Molecular Weight | 524.63 |
Formula | C29H32O7S |
CAS No. | 1000413-72-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Fasiglifam 1000413-72-8 Endocrinology/Hormones GPCR/G Protein GPR TAK 875 inhibit FFAR Inhibitor TAK-875 Free Fatty Acid Receptor TAK875 inhibitor